evipedia.aidev
← Back

Glucoraphanin for Health & Longevity

Evidence Review created on 08/24/2026 using AI4L / Grok 4

Also known as: 4-Methylsulfinylbutyl Glucosinolate, GRA, 4-MSB, Sulforaphane Glucosinolate, SGS, Glucoraphanine

Motivation

Glucoraphanin is a stable sulfur-containing compound stored in broccoli, broccoli sprouts, and related vegetables. It is not itself the active molecule. When plant tissue is chewed or mixed with a companion plant enzyme, it converts to sulforaphane, a short-lived compound that turns on the body’s own protective gene programs. That conversion can also happen later in the gut, with wide person-to-person differences. Interest among longevity-oriented adults comes from this role in cellular defense, blood fats, and blood-sugar control.

Broccoli sprouts can hold many times more glucoraphanin than mature heads, which is why sprouts, seed extracts, and standardized oral supplements became research tools after the compound’s identification in the early 1990s. Human trials have used drinks, soups, and tablets built around glucoraphanin, sometimes with the converting enzyme added. Product source and how the precursor converts matter when reading results, because academic patents and manufacturer-supplied extracts sit alongside independent feeding studies.

This review examines the human evidence that glucoraphanin, as food or as a standardized extract, changes outcomes relevant to long-term health, notably blood lipids, glucose control, and handling of airborne pollutants. It also covers conversion biology, safety including thyroid questions, formulation quality, and how trial protocols map onto practical use.

Benefits - Risks - Protocol - Conclusion

High-level overviews of glucoraphanin and its conversion to sulforaphane from expert interviews, practitioner commentary, and a major academic narrative review.

Fewer than five items are listed because Peter Attia, Andrew Huberman, and Lifespan.io lacked substantial dedicated coverage, and remaining hits were systematic reviews or duplicate organizations.

Grokipedia

  • Glucoraphanin

    Dedicated entry covering structure, plant biosynthesis, myrosinase conversion to sulforaphane, natural sources, and the main clinical research themes.

Examine

ConsumerLab

No ConsumerLab article dedicated to glucoraphanin was found.

Systematic Reviews

PubMed systematic reviews and meta-analyses covering glucoraphanin, sulforaphane, and Brassica glucosinolates on efficacy and on thyroid risk.

Mechanism of Action

Glucoraphanin is a water-soluble glucosinolate stored in crucifers, especially seeds and 3-day-old sprouts of Brassica oleracea. Intact tissue keeps it apart from myrosinase (a plant thioglucosidase). Chewing, blending, or adding exogenous myrosinase (mustard or daikon) hydrolyzes it to an unstable sugar-free intermediate (aglucone) that rearranges to sulforaphane, the reactive isothiocyanate behind most reported biology. Heat-sensitive epithiospecifier protein can divert that intermediate toward inactive nitrile. Mammalian cells lack myrosinase. Unconverted glucoraphanin reaching the colon can be processed by gut bacteria, with yields of a few percent to ~40%.

Sulforaphane is absorbed into plasma and erythrocytes, reaches airway mucosa, is conjugated to glutathione (the cell’s primary thiol antioxidant) via the mercapturic acid pathway (the tagging route that readies a compound for urine excretion), and excreted as sulfur-containing urinary metabolites (dithiocarbamates). Plasma half-life is 1–2 hours; gene programs last longer. Without plant myrosinase, recovery is later and lower (~10–20% of dose) than with active enzyme (~35–40%). The dominant mechanism is covalent modification of KEAP1 (Kelch-like ECH-associated protein 1, the inhibitor that holds NRF2 in the cytoplasm) cysteines, releasing NRF2 to drive antioxidant-response genes—the classic phase 2 (detoxification) set: NQO1 (NAD(P)H quinone dehydrogenase 1), glutathione S-transferases, heme oxygenase-1, and glutathione-synthesis enzymes. Secondary actions include damping of NF-κB (nuclear factor kappa B, a central inflammatory transcription factor), modest HDAC (histone deacetylase) inhibition, and suppression of hepatic glucose production. Clearance is glutathione conjugation rather than a single CYP (cytochrome P450) enzyme, though NRF2 programs can secondarily alter xenobiotic enzymes.

Historical Context & Evolution

Sulforaphane was isolated from broccoli in 1992 by Zhang, Talalay, and colleagues at Johns Hopkins as a potent monofunctional inducer of carcinogen-detoxifying enzymes (Zhang et al., 1992). The intact plant stores essentially no free sulforaphane; the stable precursor is glucoraphanin. In 1997 Fahey, Zhang, and Talalay reported that 3-day-old broccoli sprouts contain 10–100 times more glucoraphanin per gram than mature heads and reduced mammary tumors in a rodent model (Fahey et al., 1997). That finding shifted chemoprotection work from large servings of cooked broccoli toward sprouts, sprout beverages, and seed extracts.

Johns Hopkins patented sprout-related technology and licensed it; Brassica Protection Products (TrueBroc) and later Nutramax (Avmacol) commercialized glucoraphanin with or without myrosinase. Early human work in Qidong, China, tested sprout beverages against aflatoxin biomarkers, then against airborne benzene and acrolein. Parallel European work bred high-glucoraphanin broccoli (Beneforte) for feeding trials. More than 50 clinical studies have used glucoraphanin-rich or sulforaphane-rich matrices. Interpretation has moved from “broccoli prevents cancer” toward a narrower claim: conversion-dependent NRF2 induction with mixed clinical endpoints. Commercial and academic interests overlap; several pivotal pharmacokinetic and Qidong papers come from groups connected to the licensed technology, which is evidence to weigh, not a reason to discard the primary data.

Expected Benefits

High 🟩 🟩 🟩

Lower low-density lipoprotein cholesterol

Two independent 12-week randomized feeding trials in adults compared 400 g/week of high-glucoraphanin broccoli with standard broccoli. The high-glucoraphanin arms lowered low-density lipoprotein cholesterol, a validated cardiovascular surrogate, more than standard broccoli, consistent with sulforaphane-driven lipid handling after conversion. The contrast isolates glucoraphanin density rather than vegetables in general. These were food interventions, not isolated-tablet trials.

Magnitude: 7.1% (95% confidence interval −1.8% to −12.3%) and 5.1% (95% confidence interval −2.1% to −8.1%) reductions versus baseline in the two high-glucoraphanin arms; combined, high-glucoraphanin broccoli reduced this cholesterol fraction more than standard broccoli (Armah et al., 2015).

Medium 🟩 🟩

Improved liver enzymes in fatty liver

In Japanese men with fatty liver, two months of glucoraphanin sprout extract lowered alanine aminotransferase (ALT) and γ-glutamyl transpeptidase (GGT), clinical liver enzymes, versus baseline, in line with reduced hepatic oxidative stress; placebo did not. A 24-week glucoraphanin randomized trial in middle-aged adults with high-normal enzymes also improved ALT versus placebo. Kagome supplied both products. The fatty-liver series was small and male-only (Kikuchi et al., 2015; Satomi et al., 2022).

Magnitude: Median ALT 54.0 to 48.5 IU/L and GGT 51.5 to 50.0 IU/L after 2 months of glucoraphanin extract (Kikuchi et al., 2015).

Reduced Helicobacter pylori colonization markers

Eight weeks of broccoli sprouts providing 420 μmol glucoraphanin daily lowered urea-breath-test and stool-antigen measures of Helicobacter pylori (a stomach bacterium linked to ulcers and gastric cancer) versus alfalfa placebo; markers returned after stopping. This is colonization reduction, not eradication, likely from sulforaphane’s gastric antimicrobial and cytoprotective action (Yanaka et al., 2009).

Magnitude: Direction of lower urease and stool-antigen signals during 8 weeks of 70 g/day sprouts (420 μmol glucoraphanin); the literature report no pooled eradication-rate figure (Yanaka et al., 2009).

Improved memory scores in at-risk older adults

A 42-month randomized, placebo-controlled pilot tested 30 mg/day glucoraphanin in older adults with memory impairment. Memory Performance Index (MPI, a validated mild-cognitive-impairment screen score) improved more than placebo over the full period, a result tied to long-term NRF2 cytoprotection; conversion between impairment and normal cognition did not differ. Kagome supplied the product. The series was small (19 completers) (Shimizu et al., 2026).

Magnitude: Direction of greater Memory Performance Index improvement versus placebo over 42 months of 30 mg/day glucoraphanin; the literature report no pooled point-change figure (Shimizu et al., 2026).

Low 🟩

Improved glycemic control ⚠️ Conflicted

Lantmännen extract lowered fasting glucose and glycated hemoglobin (HbA1c) in obese type 2 diabetes by suppressing hepatic glucose production (Axelsson et al., 2017). A prediabetes trial missed its fasting-glucose target except in conversion-gene carriers (Dwibedi et al., 2025). Net reading: benefit clusters in dysglycemic converters, not uniformly.

Magnitude: Prediabetes trial overall fasting-glucose change −0.2 mmol/L (95% confidence interval −0.44 to −0.01) versus placebo, missing the 0.3 mmol/L primary target; responders −0.4 mmol/L (Dwibedi et al., 2025).

Increased urinary excretion of air-pollutant conjugates

Qidong randomized trials of broccoli-sprout beverages increased urinary glutathione conjugates of benzene and acrolein. A dose-finding study found benzene-conjugate increases only at the highest dose. These are detoxification biomarkers, not disease events, from groups linked to Johns Hopkins sprout patents (Egner et al., 2014; Chen et al., 2019).

Magnitude: Benzene mercapturate +61% and acrolein +23% versus placebo over 12 weeks (Egner et al., 2014); benzene +63.2% only at the high dose in the de-escalation trial (Chen et al., 2019).

Prostate biochemical and transcriptomic signals ⚠️ Conflicted

A sprout-extract trial in recurrent prostate cancer missed its primary ≥50% prostate-specific antigen (PSA) drop while lengthening PSA doubling time (Alumkal et al., 2015). A high-glucoraphanin soup trial changed prostate gene programs (Traka et al., 2019). Net reading: no confirmed cancer-endpoint benefit.

Magnitude: On-treatment PSA doubling time 6.1 to 9.6 months in the extract series, with only 1 of 20 men reaching a ≥50% PSA decline (Alumkal et al., 2015).

Speculative 🟨

Healthspan via NRF2 programs

Rodent and cell work links glucoraphanin-derived sulforaphane to carcinogen handling, metabolic stress resistance, and NRF2-driven cytoprotection. No human lifespan, healthspan, or validated aging-clock outcome exists for glucoraphanin; the basis is mechanistic and preclinical only.

Histone-deacetylase and epigenetic effects

Sulforaphane inhibits histone deacetylases in cells and some human blood samples. Whether that changes cancer or aging in people using glucoraphanin has not been shown; the basis is mechanistic only.

Induction of airway phase 2 enzyme RNA

A sprout-homogenate trial induced nasal glutathione S-transferase P1 (GSTP1) and NQO1 RNA. This is gene expression, not a clinical airway outcome; the basis is a pharmacodynamic biomarker only (Riedl et al., 2009).

Benefit-Modifying Factors

  • GSTM1 genotype: Deletion of GSTM1 (glutathione S-transferase mu 1, a detoxification enzyme) slightly raises circulating sulforaphane metabolites after broccoli, while epidemiology often attributes more cancer-risk reduction to GSTM1-positive people (Gasper et al., 2005).
  • Gut conversion genes: A Bacteroides operon for glucoraphanin hydrolysis tracked with higher sulforaphane exposure and larger fasting-glucose drops in prediabetes; low converters gain little from enzyme-free extracts (Dwibedi et al., 2025).
  • Baseline glycemia and adiposity: Glycemic signals concentrated in obese, poorly regulated type 2 diabetes, not in unselected prediabetes (Axelsson et al., 2017; Dwibedi et al., 2025).
  • Sex: The fatty-liver extract trial enrolled men only (Kikuchi et al., 2015); prostate work is male by design. No established dose split by sex for metabolic endpoints.
  • Age: Older adults appear in prostate, kidney-disease, and memory-impairment protocols; gut conversion and myrosinase-free bioavailability may be less predictable with age and polypharmacy.
  • Myrosinase co-delivery: Active plant enzyme raises sulforaphane recovery about 3- to 4-fold versus glucoraphanin alone (~10% versus ~35–40% of dose) (Fahey et al., 2015).
  • Pre-existing liver fat or dyslipidemia: Enzyme and cholesterol changes were measured in people who already had fatty liver or mixed lipids, not in fully optimized metabolic profiles.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal symptoms

The principal treatment-emergent effects in broccoli-sprout-extract trials are gas, bloating, abdominal discomfort, and sulfur taste or odor from unconverted glucosinolate reaching the colon. A 12-week prediabetes extract trial reported gastrointestinal side effects without severe adverse events (Dwibedi et al., 2025). A phase I sprout-extract study found no consistent laboratory toxicity at repeated doses (Shapiro et al., 2006). A cancer-trial review likewise reported no excess serious events versus controls (ElKhalifa et al., 2023).

Magnitude: Direction of mild gastrointestinal events as the main extract-related effects; the literature report no pooled incidence figure across glucoraphanin trials (Dwibedi et al., 2025; Shapiro et al., 2006).

Medium 🟥 🟥

No risk reaches Medium: remaining human data are a null thyroid-lab trial, not a single-trial clinical adverse-event endpoint.

Low 🟥

Thyroid and goitrogen concern

Crucifers raise goiter concern via iodine-uptake interference. A 12-week sprout beverage did not change thyroid labs or autoimmunity in women (Chartoumpekis et al., 2019). A 2024 review found little harm with adequate iodine (Galanty et al., 2024). Trial-dose glucoraphanin has not disturbed thyroid labs.

Magnitude: No change in thyroid-stimulating hormone (TSH), free thyroxine, or thyroglobulin after 84 days of high-glucoraphanin beverage versus control (Chartoumpekis et al., 2019).

Speculative 🟨

Altered xenobiotic-enzyme tone

NRF2 programs can change glutathione conjugation and some CYP activities, which could shift co-administered drug levels. Human glucoraphanin trials have not shown a clinical drug-interaction event; the basis is mechanistic only (Shapiro et al., 2006).

NRF2 duality in established cancer

Persistent NRF2 activation can favor some established tumors in preclinical models. Human glucoraphanin trials have not shown cancer promotion; the basis is mechanistic and animal only.

Brassica-food allergy and sprout pathogens

True allergy to broccoli-family foods is uncommon. Home-sprouted seeds carry a separate foodborne-pathogen risk that is not a property of purified glucoraphanin; the basis is isolated reports only.

Seizure in people with prior seizure disorder

A consumer drug monograph notes rare seizures after sulforaphane in people with a seizure history; causality is unclear. Glucoraphanin trials have not shown this event. The basis is isolated reports only.

Risk-Modifying Factors

  • Iodine status: Goitrogen risk, where it exists, tracks iodine deficiency plus very high raw Brassica intake, not trial doses of glucoraphanin isolate (Galanty et al., 2024).
  • GSTM1/GSTT1 genotype: Variants in glutathione S-transferases, including GSTT1 (glutathione S-transferase theta 1), change sulforaphane kinetics and conjugation load (Gasper et al., 2005).
  • Baseline liver enzymes: Higher starting ALT or GGT defined the fatty-liver extract cohort in which small enzyme improvements were measured (Kikuchi et al., 2015).
  • Sex: Thyroid-safety data from Qidong were analyzed in women (Chartoumpekis et al., 2019); no sex-specific adverse-event excess is established.
  • Age: Older adults have more co-medications whose metabolism could intersect NRF2 programs; gastrointestinal tolerance may also be lower.
  • Myrosinase-free high doses: Enzyme-free glucoraphanin at hundreds of micromoles increases unconverted substrate in the colon and the chance of gas and bloating.

Key Interactions & Contraindications

  • Antibiotics (amoxicillin, metronidazole, other broad-spectrum agents) — caution: Reduce myrosinase-producing gut flora and can collapse conversion of enzyme-free glucoraphanin to sulforaphane; co-deliver plant myrosinase or pause enzyme-free extracts until flora recover.
  • Narrow-index CYP substrates (warfarin, some immunosuppressants, some antipsychotics) — monitor: NRF2-driven conjugation may change drug exposure; glucoraphanin lacks a mapped clinical interaction with CYP3A4 (a major drug-metabolizing enzyme; ketoconazole, ritonavir, grapefruit).
  • Acetaminophen — caution: Shared glutathione handling means high-dose acetaminophen plus a new NRF2 inducer is a theoretical liver-stress pairing; keep acetaminophen within labeled limits and watch ALT.
  • Thyroid hormone (levothyroxine) and iodine — caution: Whole raw crucifers in iodine deficiency can compete for iodine uptake; standardized glucoraphanin did not change thyroid labs, but thyroid-hormone users still warrant TSH checks.
  • Other NRF2 inducers (curcumin, bardoxolone-class agents, high-dose green-tea catechins) — monitor: Additive cytoprotective signaling is plausible; combined high-dose stacks are untested for dual NRF2 over-activation.
  • Mustard, daikon, or myrosinase powders — potentiating: Exogenous myrosinase roughly doubles to quadruples sulforaphane recovery and can unmask gastrointestinal effects at the same precursor dose (Fahey et al., 2015).
  • N-acetylcysteine and glutathione donors — potentiating: Provide substrate for the same mercapturic pathway; generally complementary, not a contraindication.
  • Proton-pump inhibitors (omeprazole, esomeprazole, acid-reducing medications) — monitor: Altered gastric pH may change myrosinase survival; evidence is indirect—prefer enteric-protected or later-intestine conversion strategies if used together.

Populations who should avoid glucoraphanin:

  • Known allergy to broccoli or other Brassica foods (absolute contraindication for food and extracts from that biomass).
  • Infants given home-sprouted seeds (foodborne-pathogen risk of sprouts, not the isolated molecule).
  • Pregnancy or breastfeeding at extract or high-sprout doses rather than ordinary food amounts (safety data for medicinal doses are insufficient).
  • Uncontrolled hypothyroidism with documented iodine deficiency when the form is large amounts of raw cruciferous vegetables rather than a standardized extract.

Risk Mitigation Strategies

  • Myrosinase-standardized starting dose: Trial-type tablets at 30 mg glucoraphanin plus active myrosinase limit colon gas from unconverted substrate while raising sulforaphane recovery.
  • One- to two-week titration: Protocols typically move from one to two tablets, or from ~30 g to ~70 g sprouts, only while gastrointestinal symptoms stay mild, reducing bloating dropout.
  • Iodine-sufficient diet: Iodized salt or seaweed plus a baseline TSH check lowers residual goitrogen concern before high raw-crucifer loads.
  • Hold enzyme-free high doses after antibiotics: A 2-week pause after broad-spectrum antibiotics, or a switch to a myrosinase-containing product, limits colon gas from unconverted substrate when gut conversion falls.
  • Acetaminophen dose discipline: Keeping acetaminophen at labeled doses and rechecking ALT during febrile illness limits glutathione-pathway overlap with glucoraphanin.
  • Food-safe sprouts: Commercial sprouts or closed home sprouters with rinsed seed reduce the separate pathogen risk of homemade sprouts.
  • Twelve-week thyroid recheck if already treated: Repeating TSH at the Qidong beverage duration detects delayed thyroid-lab drift.

Therapeutic Protocol

  • Standard practitioner form: Longevity-oriented protocols typically use a glucoraphanin-plus-myrosinase tablet (Avmacol-type, Johns Hopkins–licensed) at 30–60 mg glucoraphanin daily, or 30–70 g chewed 3-day broccoli sprouts (Fahey et al., 2015).
  • Food-first alternative: Quadram high-glucoraphanin broccoli at 400 g/week was the LDL (low-density lipoprotein) cholesterol-lowering matrix; mustard powder on cooked broccoli restores conversion when myrosinase was heat-killed (Armah et al., 2015).
  • High-exposure research form: Qidong beverages used 600 μmol glucoraphanin (~262 mg) plus 40 μmol sulforaphane daily—above usual supplement labels (Egner et al., 2014).
  • Time of day: Prediabetes extract was taken once in the morning; eructation (belching) with sulfur odor is often less bothersome with breakfast than late evening (Dwibedi et al., 2025).
  • Half-life: Plasma sulforaphane half-life is about 1–2 hours; NRF2 gene programs persist longer, which is why once-daily dosing is used despite short circulating half-life (Shapiro et al., 2006).
  • Single versus split: Doses ≤60 mg glucoraphanin with myrosinase are usually once daily; enzyme-free 200–600 μmol loads are often split to limit gastrointestinal load.
  • Genetics: GSTM1-null status changes metabolite curves; a Bacteroides conversion operon predicts enzyme-free extract response more than MTHFR (a folate enzyme) or APOE4 (a lipid-gene variant) (Dwibedi et al., 2025).
  • Sex: No established mg/kg split; prostate protocols are male, fatty-liver extract data are male, thyroid-safety analyses include women.
  • Age: Older adults may use the 30 mg myrosinase-standardized starting dose because conversion and polypharmacy are less predictable.
  • Baseline biomarkers: Higher LDL cholesterol, fatty-liver enzymes, or poorly regulated glucose are the settings in which trial signals appeared.
  • Pre-existing conditions: Active peptic symptoms, iodine-deficient thyroid disease, and recent antibiotics change form and monitoring more than they forbid use.

Discontinuation & Cycling

  • Duration intent: Trial exposures run weeks to 12 months; there is no evidence that glucoraphanin must be lifelong, and no evidence that brief courses change lifespan.
  • Withdrawal: No withdrawal syndrome is described; H. pylori markers and PSA slopes drifted back after stopping, consistent with loss of pharmacodynamic effect rather than rebound injury (Yanaka et al., 2009).
  • Tapering: Abrupt stop is typical in trials; tapering is not required for safety.
  • Cycling: NRF2 is inducible and does not show a well-mapped fade-out with continued use; cycling is sometimes used for cost or taste, not because efficacy has been shown to require it.
  • After antibiotics or gastrointestinal illness: Restarting a myrosinase-containing form is more reliable than restarting enzyme-free glucoraphanin immediately.

Sourcing and Quality

  • Declared glucoraphanin plus myrosinase: Labels that state milligrams of glucoraphanin (or SGS, sulforaphane glucosinolate) and the presence of active myrosinase match the better-characterized trial products; glucoraphanin-only powders rely on variable gut conversion.
  • Trial-used brands: Nutramax Avmacol (glucoraphanin plus myrosinase; Johns Hopkins license) appears in several registered trials; TrueBroc (Brassica Protection Products) is a seed-derived glucoraphanin ingredient used in bioavailability work. Manufacturer funding is a conflict to note.
  • Preformed sulforaphane is a different intervention: Stabilized sulforaphane (e.g., Prostaphane) bypasses glucoraphanin conversion and is not interchangeable on a milligram-for-milligram basis.
  • Third-party testing: Independent assays of labeled broccoli supplements require analytic verification of glucoraphanin, not the label alone (Melini et al., 2026); certificates that quantify glucoraphanin (μmol or mg) and claimed myrosinase activity are the practical filter.
  • Sprout food quality: Three-day sprouts from unsprayed seed, fully rinsed, avoid the pathogen problem of poorly controlled home sprouts; mature broccoli glucoraphanin is much lower per gram.
  • Mustard as a converter: A small amount of mustard-seed powder supplies exogenous myrosinase for cooked broccoli or enzyme-free extracts (Mastaloudis et al., 2026).

Practical Considerations

  • Time to effect: Urinary sulforaphane metabolites appear within 24 hours; lipid and enzyme changes were measured at 8–12 weeks; H. pylori markers moved by 8 weeks and relapsed after stopping.
  • Common pitfalls: Swallowing enzyme-free glucoraphanin and assuming sulforaphane dose; boiling sprouts hard enough to kill myrosinase; trusting “sulforaphane” labels that only contain precursor; expecting cancer-endpoint protection from biomarker trials.
  • Regulatory status: Glucoraphanin extracts are dietary supplements in the United States, not FDA-approved drugs; disease-treatment claims on labels are not authorized. Sprouts are conventional food.
  • Cost and access: Clinical-trial tablets typically cost tens of dollars per month; home-grown sprouts are inexpensive but require daily attention and hygiene. High-glucoraphanin fresh broccoli is cultivar-dependent and not universally sold.

Interaction with Foundational Habits

  • Sleep: Direct sleep architecture effects are not established. Indirect: evening eructation with sulfur odor or gastrointestinal discomfort can fragment sleep; morning dosing with food is the usual workaround. No trial shows improved deep sleep as a primary endpoint.
  • Nutrition: Direct and potentiating. Conversion needs myrosinase from raw sprouts, mustard, or a tablet; cooked Brassica without a converter is a weak glucoraphanin source. Adequate iodine and a mixed diet matter more than a ketogenic versus Mediterranean frame.
  • Exercise: Indirect. NRF2 tone theoretically supports recovery from oxidative training stress. A 2026 eccentric-damage crossover found no recovery effect (Cesanelli et al., 2026); an immunometabolism trial is recruiting (NCT07668596). No evidence that glucoraphanin blunts hypertrophy. Timing is not workout-critical.
  • Stress management: Indirect and weakly specified. NRF2 and inflammatory transcription intersect stress biology in cells; human cortisol or heart-rate-variability trials of glucoraphanin are lacking. No blunting of psychological stress-reduction practices is reported.

Monitoring Protocol & Defining Success

Baseline testing before starting typically includes a metabolic panel with liver enzymes, a lipid panel, fasting glucose and glycated hemoglobin, and thyroid-stimulating hormone with free thyroxine if there is a thyroid history. These values identify metabolic or hepatic starting points that trials suggest may track with response, and they document thyroid status before a cruciferous concentrate is added. Repeat the same set at 8–12 weeks, matching common trial lengths, then every 6–12 months during continued use. Urinary sulforaphane metabolites confirm conversion in research labs but are not a routine clinic test. After recent antibiotics, a later lab set is more informative than an immediate one for enzyme-free products. Success is a stable or improved lipid and glucose profile without gastrointestinal dropout or thyroid-lab drift, plus subjective tolerance.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
LDL-C <100 mg/dL (<70 mg/dL if high cardiovascular risk) Tracks the replicated broccoli feeding signal Low-density lipoprotein cholesterol. Conventional often accepts <130 mg/dL; fasting 9–12 h; pair with apolipoprotein B if available
HbA1c (glycated hemoglobin) 4.8–5.3% Captures 2–3 month glucose exposure Conventional prediabetes starts at 5.7%; no fasting needed
Fasting glucose 75–90 mg/dL (4.2–5.0 mmol/L) Matches trial glycemic endpoints Fasting 8–12 h; interpret with insulin if insulin resistance is the question
ALT (alanine aminotransferase) <25–30 U/L Fatty-liver extract trials used this enzyme Conventional upper limits often 40–55 U/L; avoid heavy alcohol 48 h before
GGT (γ-glutamyl transpeptidase) <20–30 U/L Second liver enzyme that moved with glucoraphanin Conventional limits are higher; alcohol and some drugs raise GGT independently
TSH (thyroid-stimulating hormone) 0.5–2.5 mIU/L Documents thyroid status before a Brassica concentrate Conventional 0.4–4.5 mIU/L; pair with free T4; morning draw preferred
  • Energy and post-meal glucose steadiness over 8–12 weeks
  • Gastrointestinal comfort (gas, bloating, sulfur taste) as a tolerability gate
  • Subjective training recovery if exercise is a stated goal
  • Absence of new cold intolerance, palpitations, or neck fullness that would prompt thyroid retesting

Emerging Research

  • Tobacco-carcinogen detoxification (Avmacol ES): Phase 2 randomized trial in heavy smokers testing whether broccoli seed and sprout extract sustains benzene and acrolein detoxification (NCT05121051; n=135, recruiting). A null or positive result would tighten or weaken the pollutant-handling claim.
  • Psychosis conversion (DROPS): Phase 3 multicenter trial of sulforaphane for 2-year psychosis conversion in clinical high-risk adults (NCT03932136; n=300, active, not recruiting). A positive conversion endpoint would expand psychiatric use; a null would confine prior schizophrenia-scale signals.
  • Anthracycline cardioprotection: Phase 1/2 trial of sulforaphane around doxorubicin in breast cancer (NCT03934905; n=70, recruiting). Cardiac-function benefit would support a new risk-mitigation use; harm or null would keep cardioprotection preclinical.
  • Chronic kidney disease (completed): Randomized Avmacol Extra Strength trial in chronic kidney disease (CKD) stages 3–4 with plasma 8-isoprostane as primary (NCT05797506; n=96, completed, results posted). Peer-reviewed outcomes could support or weaken kidney-oxidative claims.
  • Firefighter carcinogen detoxification: Phase 2 broccoli seed and sprout extract trial (NCT06009926; n=72, active, not recruiting) tests occupational-exposure handling beyond the Qidong air-pollution setting.
  • Neurodegenerative glucoraphanin plus myrosinase: Open recruitment of a glucoraphanin–myrosinase composition in Parkinson disease and related conditions (NCT07360977; n=300). A UPDRS (Parkinson motor-scale) move would be new; failure would keep neurology claims speculative.
  • Gut conversion as an effect modifier: The 2025 prediabetes trial’s Bacteroides operon finding, if replicated, could reclassify enzyme-free glucoraphanin as a microbiome-dependent intervention rather than a universal extract (Dwibedi et al., 2025).

Conclusion

Glucoraphanin is the stable broccoli-family precursor that becomes sulforaphane after contact with a plant enzyme or, less predictably, after gut bacteria act on it. Standardized extracts and high-glucoraphanin vegetables are the forms studied for long-term health. The strongest human signal is a modest drop in low-density lipoprotein cholesterol with high-glucoraphanin broccoli in two independent feeding trials. Glucose control improved in obese people with poorly regulated type 2 diabetes in one extract trial and did not meet its pre-set fasting-glucose target in a later prediabetes trial, with response tied to baseline metabolism and a bacterial gene for conversion. Small improvements in liver enzymes, reduced stomach-bacteria markers, better memory-test scores in a small older-adult extract study, and higher urinary elimination of some air-pollutant breakdown products appear in other trials. Cancer-related blood markers have been mixed. Gastrointestinal discomfort is the main replicated inconvenience. A twelve-week high-dose beverage did not disturb thyroid hormone or tests that look for the body attacking the thyroid. Conversion without the plant enzyme is often low and highly individual. Much of the early chemistry and several key trials come from groups that later licensed sprout technology, and some extract trials used manufacturer-supplied product. For a risk-aware adult already managing food, sleep, and training, glucoraphanin is a well-tolerated input whose effects depend on how well the precursor converts, touching blood fats, blood sugar, and how the body clears some airborne pollutants, rather than a demonstrated extender of lifespan.

Top - Benefits - Risks - Protocol